Star-Pen (Granules) Instructions for Use
Marketing Authorization Holder
Sandoz, GmbH (Austria)
ATC Code
J01CE02 (Phenoxymethylpenicillin)
Active Substance
Phenoxymethylpenicillin (Rec.INN registered by WHO)
Dosage Form
| Star-Pen | Granules for the preparation of an oral suspension 400 thousand IU/5 ml: bottle 60 ml |
Dosage Form, Packaging, and Composition
| Granules for the preparation of an oral suspension | 5 ml of prepared susp. |
| Phenoxymethylpenicillin potassium | 400000 IU |
4800000 IU – Dark glass bottles with a volume of 60 ml (1) – cardboard packs.
Clinical-Pharmacological Group
Penicillin antibiotic, destroyed by penicillinase
Pharmacotherapeutic Group
Antibiotic, penicillin
Pharmacological Action
An antibiotic from the group of biosynthetic penicillins. The mechanism of action is associated with the inhibition of bacterial cell wall synthesis. It acts bactericidally. Acid-resistant.
Active against aerobic gram-positive bacteria: Staphylococcus spp., Streptococcus spp. (including Streptococcus pneumoniae), Enterococcus spp. (some strains), Clostridium spp., Corynebacterium spp., Erysipelothrix rhusiopathiae, Listeria spp., Bacillus anthracis, Actinomyces spp.; aerobic gram-negative bacteria: Neisseria meningitidis, Neisseria gonorrhoeae; Pasteurella multocida, Streptobacillus spp.; anaerobic bacteria: Peptococcus spp., Peptostreptococcus spp., Fusobacterium spp., Clostridium spp.
Also active against Spirullinum minus, Treponema pallidum, Borrelia spp., Leptospira interrogans.
Staphylococcus spp. (strains producing penicillinase) are resistant to phenoxymethylpenicillin.
Pharmacokinetics
Phenoxymethylpenicillin is acid-resistant, not destroyed in the acidic environment of the stomach. Absorption in the alkaline environment of the small intestine is 30-60%. Plasma protein binding is 60-80%. Cmax is reached 30-60 minutes after administration. Phenoxymethylpenicillin penetrates into the kidneys, liver, skin, lungs, mucous membrane, muscles, wall of the small intestine and into most body fluids, especially in the presence of inflammatory processes; lower concentrations are determined in bone tissue. It crosses the placental barrier and is found in small amounts in breast milk. About 30-35% is metabolized in the liver. T1/2 is 30-60 minutes. It is excreted mainly by the kidneys unchanged (25%) and in the form of metabolites (35%); about 30% is excreted through the gastrointestinal tract.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to phenoxymethylpenicillin, including bronchitis, pneumonia, tonsillitis, scarlet fever, otitis media, gonorrhea, syphilis, tetanus, anthrax, purulent diseases of the skin and soft tissues.
For prophylaxis: wounds of various etiologies (including bites); burns; prevention of streptococcal infections and their complications (including rheumatism /rheumatic attack, chorea minor/, polyarthritis, glomerulonephritis, endocarditis); prevention of bacterial endocarditis in patients with congenital or acquired rheumatic heart defects before and after minor surgical interventions (tonsillectomy, tooth extraction); prevention of pneumococcal pneumonia in children with sickle cell anemia; prevention of rheumatism exacerbations.
ICD codes
| ICD-10 code | Indication |
| A22 | Anthrax |
| A35 | Other forms of tetanus |
| A38 | Scarlet fever |
| A51 | Early syphilis |
| A52 | Late syphilis |
| A54 | Gonococcal infection |
| H66 | Suppurative and unspecified otitis media |
| I00 | Rheumatic fever without mention of heart involvement |
| I01 | Rheumatic fever with heart involvement |
| I02 | Rheumatic chorea |
| I33 | Acute and subacute endocarditis |
| J03 | Acute tonsillitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J42 | Unspecified chronic bronchitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| M05 | Seropositive rheumatoid arthritis |
| M13.9 | Arthritis, unspecified |
| M15 | Polyosteoarthritis |
| N00 | Acute nephritic syndrome (acute glomerulonephritis) |
| N03 | Chronic nephritic syndrome |
| N51 | Disorders of male genital organs in diseases classified elsewhere |
| N74.3 | Gonococcal inflammatory diseases of female pelvic organs |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T14.1 | Open wound of unspecified body region |
| T30 | Burns and corrosions of unspecified body region |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Z29.2 | Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes) |
| ICD-11 code | Indication |
| 1A61.Z | Early syphilis, unspecified |
| 1A62.Z | Late syphilis, unspecified |
| 1A7Z | Gonococcal infection, unspecified |
| 1B40.0 | Rheumatic arthritis, acute or subacute |
| 1B40.Z | Acute rheumatic fever without mention of heart involvement, unspecified |
| 1B41.Z | Acute rheumatic heart disease, unspecified |
| 1B42 | Rheumatic chorea |
| 1B50 | Scarlet fever |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1B97 | Anthrax |
| 1C13 | Tetanus |
| 1C44 | Non-pyogenic bacterial infections of skin |
| AA9Z | Unspecified suppurative otitis media |
| BB4Z | Acute or subacute endocarditis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| FA05 | Polyosteoarthritis |
| FA20.0 | Seropositive rheumatoid arthritis |
| FA2Z | Inflammatory arthropathies, unspecified |
| GB06.0Z | Unspecified balanoposthitis |
| GB0Z | Diseases of male genital system, unspecified |
| GB40 | Nephritic syndrome |
| ND56.0 | Superficial injury of unspecified body region |
| ND56.1 | Open wound of unspecified body region |
| NE11 | Burn of unspecified body region |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| QC05.Y | Other specified prophylactic measures |
| 1A71 | Gonococcal pelviperitonitis |
| GA05.Z | Inflammatory diseases of female pelvic organs, unspecified |
| 1B40.Y | Other specified acute rheumatic fever without mention of heart involvement |
| CA40.08 | Pneumonia due to Beta-haemolytic streptococcus |
| GB40 | Nephritic syndrome |
| XT8W | Chronic course |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Individual. For moderate infections, adults and children over 10 years old – 3 million IU/day. For severe infections, the dose is increased to 6-9 million IU/day. For children under 10 years of age – 50,000-100,000 IU/kg/day. Frequency of administration – 3-6 times/day. The course of treatment is on average at least 5-7 days; when treating infections caused by β-hemolytic streptococcus – at least 7-10 days.
Adverse Reactions
Allergic reactions infrequently – urticaria, skin hyperemia, angioedema, rhinitis, conjunctivitis; rarely – fever, serum sickness, arthralgia, eosinophilia; very rarely – anaphylactic shock.
From the hematopoietic system rarely – hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia, pancytopenia.
From the digestive system infrequently – nausea, vomiting, diarrhea, glossitis, stomatitis, vesicular cheilitis, decreased appetite, dry mouth, taste disturbance; rarely – pseudomembranous colitis.
Other rarely – interstitial nephritis, vasculitis.
Contraindications
Hypersensitivity to phenoxymethylpenicillin and other beta-lactam antibiotics (penicillins, cephalosporins, carbapenems); severe course of infections (including the acute stage of severe pneumonia); gastrointestinal diseases accompanied by vomiting and diarrhea; aphthous stomatitis and pharyngitis; gastroparesis, cardia spasm or increased intestinal motility; children’s age – depending on the dosage form.
With caution
In allergic diseases (bronchial asthma, hay fever, diathesis), allergic reactions (in history).
Use in Pregnancy and Lactation
During pregnancy, it is possible to use according to indications in cases where the intended benefit to the mother outweighs the potential risk to the fetus. If it is necessary to use during lactation, the issue of stopping breastfeeding should be decided.
Pediatric Use
It is possible to use in children according to indications, in doses and dosage forms recommended according to age. It is necessary to strictly follow the instructions in the instructions for phenoxymethylpenicillin preparations regarding contraindications for the use of specific dosage forms of phenoxymethylpenicillin in children of different ages.
Special Precautions
If allergic reactions develop, Phenoxymethylpenicillin should be discontinued and appropriate therapy prescribed.
The use of phenoxymethylpenicillin in combination with bacteriostatic antibiotics should be avoided. Combination with other antibiotics is allowed if an additive or synergistic effect is expected.
During long-term treatment, the possibility of growth of resistant strains of bacteria and fungi should be taken into account.
In case of persistent diarrhea, the possibility of developing pseudomembranous colitis should be considered.
With prolonged use, periodic monitoring of the peripheral blood picture and indicators of liver and kidney function is recommended.
When using phenoxymethylpenicillin, false-positive results are possible in the reaction during non-enzymatic determination of glucose in urine and in the analysis for urobilinogen and the results of quantitative determination of amino acids in urine by the ninhydrin method.
Effect on the ability to drive vehicles and mechanisms
During the use of phenoxymethylpenicillin, patients should be careful when driving vehicles and mechanisms, as well as when engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Drug Interactions
With simultaneous use, Phenoxymethylpenicillin increases the effectiveness of indirect anticoagulants (by suppressing the intestinal microflora, it reduces the formation of vitamin K); reduces the effectiveness of oral contraceptives and drugs in the process of metabolism of which para-aminobenzoic acid is formed.
With simultaneous use, Phenoxymethylpenicillin increases the risk of “breakthrough” bleeding while taking ethinyl estradiol.
With simultaneous use, antacids, glucosamine, laxatives, aminoglycosides and food slow down and reduce the absorption of phenoxymethylpenicillin; ascorbic acid increases it.
With simultaneous use of bactericidal antibiotics (including cephalosporins, cycloserine, vancomycin, rifampicin), aminoglycosides, synergism of action is observed; with simultaneous use of bacteriostatic antibiotics (including macrolides, chloramphenicol, lincosamides, tetracyclines) – antagonism.
With simultaneous use, diuretics, allopurinol, phenylbutazone, NSAIDs and other drugs that reduce tubular secretion increase the concentration of phenoxymethylpenicillin and enhance its effect.
With simultaneous use of phenoxymethylpenicillin and allopurinol, the risk of developing allergic reactions (skin rash) increases.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
No-spa pills 40mg, 64pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Mildronate capsules 500mg, 90pcs
Belosalic, ointment, 30g
Ingavirin capsules 90mg, 10pcs
Actovegin pills 200mg, 50pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Arbidol, capsules 100mg, 40pcs
Nootropil pills 800mg, 30pcs 